Nuvectis Pharma, Inc.
NVCT
$18.96
-$0.27-1.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.22M | 9.69M | 9.42M | 8.84M | 8.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.87M | 28.27M | 27.57M | 26.41M | 22.97M |
| Operating Income | -28.87M | -28.27M | -27.57M | -26.41M | -22.97M |
| Income Before Tax | -27.85M | -27.16M | -26.44M | -25.38M | -22.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.85 | -27.16 | -26.44 | -25.38 | -22.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.85M | -27.16M | -26.44M | -25.38M | -22.07M |
| EBIT | -28.87M | -28.27M | -27.57M | -26.41M | -22.97M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.31 | -1.31 | -1.31 | -1.35 | -1.16 |
| Normalized Basic EPS | -0.75 | -0.75 | -0.75 | -0.78 | -0.72 |
| EPS Diluted | -1.31 | -1.31 | -1.31 | -1.35 | -1.16 |
| Normalized Diluted EPS | -0.75 | -0.75 | -0.75 | -0.78 | -0.72 |
| Average Basic Shares Outstanding | 92.81M | 90.70M | 87.22M | 81.78M | 76.29M |
| Average Diluted Shares Outstanding | 92.81M | 90.70M | 87.22M | 81.78M | 76.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |